Triple-threat approach can reduce invasive bloodstream infections in pediatric cancer patients

NewsGuard 100/100 Score

Hospitals can dramatically reduce the number of life-threatening central line infections in pediatric cancer patients by following a set of basic precautions, by encouraging families to speak up when they observe noncompliance with the protocol and by honest analysis of the root cause behind every single infection, according to a new Johns Hopkins Children's Center study.

In a report in the October issue of Pediatrics, published online Sept. 3, the researchers say this triple-threat approach has prevented one in five infections over two years.

Previous studies from Johns Hopkins and other institutions have demonstrated that meticulous daily care of the central line can cut the number of bloodstream infections in critically ill patients, but this is the first study, the researchers say, to focus on the most vulnerable of pediatric patients - those undergoing cancer treatment and bone marrow transplants.

A central venous catheter, or central line, is a tube inserted into a major blood vessel in the neck, chest or groin as a portal for medication, fluids or blood draws.
Inserted incorrectly or mishandled after insertion, the central line can become a gateway for bacteria and other germs into the patient's bloodstream, causing invasive disease and organ damage. Because nurses and doctors access the catheter several times a day -- as much as 10 to 30 times daily in oncology patients, researchers say -- proper handling of the device is critical.

"Children receiving cancer treatment are uniquely prone to invasive bloodstream infections because of their weakened immunity and because their central lines are accessed multiple times a day, with each entry posing a risk for infection," says lead investigator Michael Rinke, M.D., a pediatrician and a patient safety expert at the Johns Hopkins Children's Center.

The current study was carried out by pediatric oncology nurses, physicians and safety experts at the Johns Hopkins pediatric inpatient cancer unit. To keep bacteria and other pathogens at bay, the nurses deployed strict device-handling precautions that included -- among other things -- frequent and regular changing of the dressing covering the central line; regular changing of the tubes and caps attached to central line; cleaning of the line before and after each use; use of facial mask and gloves when handling the device; and hand-washing before and after handling the line.

In a novel twist, the Johns Hopkins investigators asked parents to provide additional oversight, equipping them with wallet flash cards on the "do's" and "don'ts" of central line care.

"Parents can act as an invaluable second set of eyes, and we urged them to be vigilant about the way their child's central line was handled." says co-investigator
Kim Drucis, M.S.N., R.N., a pediatric oncology nurse. "We also encouraged them to ask questions and to speak up every time they noticed something different."

The oncology nurses also held monthly briefings to discuss every infection that occurred during the study. Such root-cause analysis is already a staple of error reduction in other industries including airline, nuclear and military.

"Honest dissection of one's practice is neither easy nor pleasant but is absolutely critical to illuminate areas for improvement," says co-investigator Stephanie Panton, M.S.N., R.N., C.P.O.N.

The approach reduced infections by 20 percent over two years. During year one, the infection rate remained unchanged but in the second year, infections plummeted by 64 percent -- a delayed ramp-up effect that points to the often-slow pace of meaningful change, the investigators say.

"Real change rarely occurs overnight. It requires sustained effort and unwavering focus, day after day, month after month, year after year," Rinke says. "It's a slow, arduous process, but the payoff can be dramatic."

Source:

Pediatrics

Comments

  1. Victoria vonLinsowe Victoria vonLinsowe United States says:

    My 3 year old grandson was diagnosed with Anaplastic Apendymoma.  His tumor was discovered August 2, last month.  He spent 10 days in the hospital, received initial tumor removal of which we were told was about 60%.  Then second surgery to put in shunt.  One week upon his discharge he became extremely ill, and it was determined he had an infection.  He spent 7 days on one antibiotic with no improvement.  Then they finally changed his antibiotic, and started to show good improvement within 2 days.   The 2nd week, a team of infectious Dr's were in and told us that they were going to recommend neurology, that his new shunt should not be put in until he was on the new antibiotic for a total of 10 days.  The next day, neurology comes in and says his shunt surgery is a go for the following day.  I knew right away that must have meant neurology nixed the advice.  The surgery started then stopped, due to coming across infection.  This poor baby has been through the ringer, his surgery to have his port put in has also been delayed, delaying cancer treatment.  I'm beyond concerned about the care he has received, and am leary now about his cancer care to now continue at this hospital.  Are my fears justified, and what questions should we be asking.

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
UCLA study finds pre-surgery immunotherapy safe for pancreatic cancer patients